![](/img/cover-not-exists.png)
PCV71 COST-EFFECTIVENESS OF EZETIMIBE/SIMVASTATIN VERSUS SIMVASTATIN: WILL THE INCREASED RISK OF CANCER MAKE EZETIMIBE/SIMVASTATIN AN INAPPROPRIATE TREATMENT CHOICE?
CC Wang, AK Biddle, JF FarleyVolume:
12
Year:
2009
Language:
english
DOI:
10.1016/s1098-3015(10)73832-8
File:
PDF, 89 KB
english, 2009